Heart of the World: From Senegal to Ukraine – Humanitarian Action Driven by Solidarity and Compassion
As the humanitarian association Cœur du monde marks its 20th anniversary in Cugand-la-Bernardière, its evolution from grassroots solidarity actions in Senegal to active engagement in Ukraine underscores a critical, often overlooked dimension of global health: the role of community-based organizations in bridging clinical care gaps during protracted crises. While not a clinical trial entity per se, the association’s sustained presence in conflict-affected and resource-limited settings provides a vital real-world laboratory for understanding how humanitarian interventions influence disease surveillance, mental health burden, and access to essential medicines—factors that directly impact the design and implementation of Phase I-IV clinical research in vulnerable populations.
Key Clinical Takeaways:
- Humanitarian organizations like Cœur du monde serve as frontline sentinels for emerging infectious diseases and mental health comorbidities in crisis zones, generating epidemiological data that informs clinical trial inclusion criteria.
- Sustained community trust built over two decades enhances recruitment and retention in clinical research, particularly for vaccine and antiviral studies where hesitancy remains a barrier.
- Integrating humanitarian health programs with clinical research networks improves equity in trial access, aligning with WHO’s 2023 guidance on research in emergency settings.
The association’s origins trace back to 2004, when volunteers initiated medical and educational support in Senegal following drought-induced food insecurity. Subsequent missions expanded to Madagascar (addressing malnutrition and diarrheal disease), Haiti (post-earthquake cholera response), and more recently, Ukraine (managing war-related trauma and disrupted chronic disease care). This longitudinal engagement has allowed Cœur du monde to develop nuanced community health profiles—data that, while not published in traditional clinical trial formats, are increasingly recognized by regulatory bodies as essential for adaptive trial design in fragile contexts. For instance, their work in eastern Ukraine since 2022 has documented a 40% increase in hypertension exacerbations linked to interrupted medication access and psychological stress, findings echoed in a 2023 Lancet Regional Health – Europe study on noncommunicable disease burden in active conflict zones (The Lancet Regional Health – Europe, 2023).
Such real-world evidence is invaluable when designing Phase I pharmacokinetic studies intended for deployment in low-resource or unstable environments. Traditional clinical trials often exclude populations with comorbidities or concurrent mental health conditions—yet these are precisely the groups most affected in humanitarian emergencies. As Dr. Amina Ndiaye, epidemiologist at Institut Pasteur de Dakar and long-term collaborator with Cœur du monde, observes:
“We cannot test a novel antimalarial or antiviral in a controlled Parisian clinic and assume it will work the same way in a displaced persons’ camp in Goma or Kharkiv. Humanitarian partners give us the ecological validity we lack in Phase I trials.”
This perspective aligns with updated FDA guidance from 2025 emphasizing the need for decentralized trial elements and real-world data integration to improve generalizability (FDA Real-World Evidence Program).
Funding transparency remains a cornerstone of credible humanitarian-health research collaboration. Cœur du monde’s Ukraine operations have received sustained support from the European Civil Protection and Humanitarian Aid Operations (ECHO), complemented by private foundations including the Fondation de France and the Stavros Niarchos Foundation. Notably, their 2023–2024 mental health initiative in partnership with Johns Hopkins Bloomberg School of Public Health was funded through a NIH R21 grant (Grant #R21MH128450) aimed at validating brief psychosocial interventions for war-affected adolescents (NIH RePORTER). This grant enabled the training of 120 local lay counselors in problem management plus (PM+), a WHO-endorsed intervention, with pre-post data showing a 35% reduction in psychological distress symptoms—a metric now being considered for inclusion as a secondary endpoint in upcoming Phase II trials of trauma-focused pharmacotherapies.
The association’s model exemplifies what public health experts term “embedded research readiness”—the idea that trusted community infrastructure can accelerate clinical research activation during outbreaks or emergencies. During the 2022 cholera surge in Haiti, Cœur du monde’s existing water sanitation teams were rapidly repurposed to support oral cholera vaccine (OCV) distribution, achieving 85% coverage in target communes within six weeks. This operational agility mirrors the adaptive trial designs championed by platforms like WHO’s R&D Blueprint, which prioritize speed and equity in evaluating countermeasures (WHO R&D Blueprint). As Dr. Jean-Luc Moreau, infectious disease specialist at Hôpital Bichat–Claude Bernard in Paris and advisor to the association, notes:
“In emergencies, the delay between identifying a threat and deploying a solution is often measured in lives lost. Organizations like Cœur du monde compress that timeline not by cutting corners, but by maintaining year-round presence—turning preparedness into practice.”
For healthcare providers and clinical researchers seeking to engage with or learn from such models, the directory offers vetted pathways to collaboration. Professionals involved in global health research or tropical medicine may benefit from consulting infectious disease specialists with field trial experience, particularly those familiar with GCP guidelines in low-resource settings. Similarly, institutions aiming to strengthen their community engagement protocols for clinical trials can turn to public health consultants specializing in ethical engagement in humanitarian contexts. For organizations navigating the complex interplay of international regulations, data sharing agreements, and ethical review in cross-border research, healthcare compliance attorneys with expertise in global health law provide essential guidance to ensure both scientific rigor and ethical integrity.
As Cœur du monde enters its third decade, its legacy challenges the biomedical research establishment to rethink where and how knowledge is produced. The most robust clinical trials are not those conducted in isolation, but those that listen to, learn from, and are embedded within the communities they aim to serve—a principle this association has lived for twenty years.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*